Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Tyrel T. Smith(Fred Hutch Cancer Center), Matthias T. Stephan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Journal of Clinical Investigation
April 23, 2017
Cited by 332


Related Papers